Ludwig Researchers Focus on a New Set of Immune Checkpoints

Anita T. Shaffer @Shaffer1
Published: Tuesday, Aug 05, 2014
Jonathan Skipper

Jonathan Skipper, PhD

Ever since ipilimumab (Yervoy) gained FDA approval in 2011 for the treatment of metastatic melanoma, the immune checkpoint blockade strategy that the agent employs has been an intense focus of interest in research and pharmaceutical circles. Now, the concept of manipulating the immune system’s regulatory processes to attack cancer is branching out in new directions.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication